The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more lucrative targeted therapies and immunotherapies class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.
Key reasons to purchase this title
- Quantify the performance of each of the marketed cancer targeted therapies and immunotherapies in the seven major markets over the period 2009 to 2019
- Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy and immunotherapy brands
- Identify the leading brands in this market over the next 10 years and understand the key factors driving their success
